Svb Leerink upgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from an underperform rating to a market perform rating in a research note released on Friday morning, BenzingaRatingsTable reports.

SAGE has been the subject of a number of other research reports. Morgan Stanley reaffirmed a buy rating and set a $217.00 price target on shares of SAGE Therapeutics in a research report on Sunday, November 24th. Piper Jaffray Companies cut their price objective on SAGE Therapeutics from $206.00 to $125.00 and set an overweight rating on the stock in a research report on Thursday. HC Wainwright reduced their target price on SAGE Therapeutics from $160.00 to $87.00 and set a neutral rating on the stock in a research note on Friday. Stifel Nicolaus reissued a buy rating on shares of SAGE Therapeutics in a research note on Wednesday, November 20th. Finally, Guggenheim decreased their target price on SAGE Therapeutics from $200.00 to $110.00 and set a buy rating for the company in a report on Thursday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $128.81.

SAGE stock opened at $64.46 on Friday. The firm’s 50-day moving average price is $142.30 and its two-hundred day moving average price is $160.81. SAGE Therapeutics has a 12-month low of $56.50 and a 12-month high of $193.56. The stock has a market capitalization of $3.34 billion, a price-to-earnings ratio of -7.98 and a beta of 2.52. The company has a current ratio of 12.67, a quick ratio of 12.67 and a debt-to-equity ratio of 0.03.

SAGE Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($3.41) by ($0.07). The firm had revenue of $3.57 million for the quarter, compared to analysts’ expectations of $2.52 million. SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The business’s revenue for the quarter was up 35600.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.63) earnings per share. Equities analysts predict that SAGE Therapeutics will post -13.77 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. Invesco Ltd. lifted its position in SAGE Therapeutics by 197.2% during the second quarter. Invesco Ltd. now owns 2,021,964 shares of the biopharmaceutical company’s stock valued at $370,201,000 after buying an additional 1,341,720 shares during the period. Nuveen Asset Management LLC bought a new stake in shares of SAGE Therapeutics during the 2nd quarter valued at $113,776,000. Jennison Associates LLC boosted its holdings in shares of SAGE Therapeutics by 25.4% during the 2nd quarter. Jennison Associates LLC now owns 2,953,913 shares of the biopharmaceutical company’s stock valued at $540,832,000 after buying an additional 598,299 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of SAGE Therapeutics by 12.3% in the 2nd quarter. Janus Henderson Group PLC now owns 1,873,408 shares of the biopharmaceutical company’s stock worth $343,002,000 after buying an additional 204,779 shares during the period. Finally, State Street Corp grew its position in shares of SAGE Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 1,039,599 shares of the biopharmaceutical company’s stock worth $145,845,000 after buying an additional 84,138 shares during the period.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Further Reading: What is quantitative easing?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.